Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Finance News Network Investor Series May 2019
19 slides from Prescient Therapeutics's conference presentation, May 21, 2019
Slide 1: Developing Personalised Medicines to Beat Cancer
For personal use only DEVELOPING PERSONALSED MEDICINES TO BEAT CANCER. Prescient Therapeutics Limited (ASX: PTX) Finance News Network Investor Series May 2019
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: Investment Summary
INVESTMENT SUMMARY For personal use only ASX code: PTX • 2 clinical stage drugs with multiple shots on goal • Only exposure to hot personalised medicine industry on ASX • Excellent team with successful track record • Collaborations with leading clinicians and hospitals • Funding in place with $9.1m
Slide 4: Prescient's Approach: Address the Mutations Causing Cancer
PRESCIENT’S APPROACH: ADDRESS THE MUTATIONS CAUSING CANCER For personal use only Cells divide Sometimes over and over mistakes are made MUTATIONS CANCER 4 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 5: Deep, Clinical Stage Product Pipeline
DEEP, CLINICAL STAGE PRODUCT PIPELINE • Deep clinical pipeline with 4 data readouts expected in the next 18 months For personal use only DISCOVERY SCREENING PRE-CLINICAL PHASE 1 PHASE 1B PHASE 2 PHASE 3 BREAST CANCER PTX-200 (Ph2 pt1 readout Q4 2019) AML PTX-200 (Ph1b readout Q3/Q4 2019) OVARIAN PTX
Slide 6: Why Is Personalised Medicine Changing the Industry?
WHY IS For personal use only PERSONALISED MEDICINE CHANGING THE INDUSTRY? 6 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 7: Problems with Current "One Size Fits All" Approaches
PROBLEMS WITH CURRENT “ONE SIZE FITS ALL” APPROACHES For personal use only • Without precision medicine, patients are treated the same regardless of the differences between individuals. • A “one size fits all” approach leads to poor outcomes, and exposure to serious risks Untargeted drug Benefit No
Slide 8: People Aren't the Same…Nor Are Tumours
PEOPLE AREN’T THE SAME…NOR ARE TUMOURS For personal use only • Personalized medicine takes into account individual tumour variability » Different tumours have different drivers! • This precise, targeted personalized therapy is a more effective way of treating cancer patients • Huge area of industry
Slide 9: Examples of Personalised Medicine Approaches
EXAMPLES OF PERSONALISED MEDICINE APPROACHES Disease Target Drug Status For personal use only Chronic Myeloid Bcr-Abl Gleevec has increased 5-year survival rate for CML from Gleevec 31% to 90% (1990s-2012) Leukemia (95% of patients) Acute Myeloid FLT3 Gilteritinib NDA filed for R/R FLT3-positive AML
Slide 10: Big Valuations and Deal Activity in This Space
BIG VALUATIONS AND DEAL ACTIVITY IN THIS SPACE For personal use only US$5B US$8B buyout by Eli Lilly Jan 2019 US$5.1B buyout by GSK Dec 2018 US$3.3B US$964M US$18B 10 GOOGLE FINANCE 20 FEB 2019
Slide 11: PTX-200 Novel AKT Inhibition
PTX-200 For personal use only NOVEL AKT INHIBITION BREAST CANCER ACUTE MYELOID LEUKEMIA OVARIAN CANCER 11 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 12: HER2- Breast Cancer Overview
HER2 - BREAST CANCER OVERVIEW For personal use only 80% OF BREAST CANCERS ARE HER2- BUT THIS IS STILL UNDERSERVED BY NEW DRUGS $10.6B $5.4B 2015 2025 12 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 13: Phase 1b Results Very Encouraging
PHASE 1B RESULTS VERY ENCOURAGING For personal use only Typical expectation with current treatments In PTX’s trial we saw 50% 25% OVERALL RESPONSE RATE IN ALL EVALUABLE PATIENTS OVERALL RESPONSE RATE 100% Visual representation of response by OVERALL RESPONSE RATE IN LOCALLY ADVANCED PATIENTS breast
Slide 14: PTX-100: Pursuing Ras and Rho Mutant Cancers
PTX-100 For personal use only PHASE 1 IN SOLID TUMORS COMPLETED NOW PURSUING A TRANSFORMATIVE OPPORTUNITY IN RAS AND RHO MUTANT CANCERS 14 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 15: Basket Trials: Taking Targeted Therapies to the Next Level
BASKET TRIALS: TAKING TARGETED THERAPIES TO THE NEXT LEVEL For personal use only • Group patients according to the mutational profile of their tumours, not on the location of tumours • “Basket” trial bundles identifies patients carrying this mutation, and switch it off with a particular targeted the
Slide 16: PTX-100 The Only Drug Targeting RhoA
PTX-100 THE ONLY DRUG TARGETING RHOA For personal use only • PTX-100 has a unique position in RhoA mutant malignancies » Only clinical stage RhoA inhibitor globally Unmet clinical • Phase 1 trial in solid tumours completed – safety profile established need • Basket PK/PD study expected to begin in Q
Slide 17: Case Study – Loxo Oncology
CASE STUDY – LOXO ONCOLOGY (NASDAQ:LOXO) • Lead drug Larotrectnib: targeted therapy for cancers with TRK fusions For personal use only • An unmet need in small patient population (2,500-3,000 cases/year in US) • Pioneered “one trial to launch” basket study Bought by • Only 4 years from initiating Ph
Slide 18: Investment Summary: A Great Launch Pad for Transformation
INVESTMENT SUMMARY For personal use only A GREAT LAUNCH PAD FOR TRANSFORMATION • PTX: only exposure to hot personalised medicine industry on ASX • 2 clinical stage drugs with multiple shots on goal » Encouraging data already unfolding in breast cancer with PTX-200 » Moonshot on PTX-100 • Excellent t
Slide 19: Contact
For personal use only CONTACT Steven Yatomi-Clarke e: steven@ptxtherapeutics.com CEO & Managing Director t: +61 417 601 440 Prescient Therapeutics Limited w: ptxtherapeutics.com 19 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Prescient Therapeutics — Finance News Network Investor Series May 2019 on 6ix